been extensively studied by aCGH. 2,7 Copy number and LOH analyses were performed using the Chromosome Copy Number Analysis Tool (version 2.0.0.9, Affymetrix) applying a 0.5 Mb genome smoothing filter.
A median number of 8 (range ¼ 5-20) pUPDs were identified in the samples, indicating that pUPD is a common phenomenon in MCL cell lines. Most interestingly, the regions of pUPD detected in the MCL cell lines affected regions of recurrent chromosomal deletion described in the aCGH studies ( Figure 1 ).
1-3 Furthermore, we found an excellent agreement between copy number changes detected by aCGH and SNParray analyses.
To study whether pUPD is common also in other types of lymphomas, we took advantage of the 10K SNP-array data publicly available from the Wellcome Trust Sanger Institute Cancer Genome Project (http://www.sanger.ac.uk/genetics/ CGP). We focused on Burkitt lymphoma (BL) cell lines because this lymphoma shows a low number of chromosomal changes in addition to the pathogenetic Burkitt translocation t(8;14) (q24;q32) or its variants. Among others, we observed recurrent pUPD in 17p and 18q in BL cell lines. Chromosome 17p contains the TP53 tumor suppressor gene, whereas 18q harbors the candidate tumor suppressor NOXA, which is homozygously deleted in a BL cell line (Mestre et al., submitted) .
In summary, these findings show pUPD to be recurrent in lymphoma and to affect regions commonly targeted by deletions. Further studies in primary tumor samples are mandatory to extend these findings, but problems of allele discrimination caused by contaminating non-neoplastic cells have to be resolved. If associating genetic findings with clinical outcome, pUPD has to be considered as a mechanism of tumor suppressor gene inactivation alternative to chromosomal deletion.
The routine use of frontline all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy has greatly improved the outcome of APL, particularly by reducing the incidence of relapses, notably early relapses. Overall, the combination of ATRA and anthracycline-based chemotherapy yields complete remission rates greater than 90% in newly diagnosed APL.
1,2
With maintenance combining continuous 6-mercaptopurine (6MP) and methotrexate (MTX) to intermittent ATRA and possibly with early introduction of chemotherapy during induction treatment, the relapse risk in APL has now been reduced to 10-15%.
1-4
Before the ATRA era, the large majority of first relapses in APL occurred within 3 years of CR achievement, and only 2-3% of the patients relapsed after 4 years. 5, 6 Theoretically, the possibility exists that the addition of ATRA to chemotherapy in newly diagnosed APL may only delay some of the relapses that were seen earlier with chemotherapy alone. The incidence and characteristics of late relapses occurring after ATRA-and anthracycline-based chemotherapy, however, are not known.
Between 1991 and 1997 (APL 91 and 93 trials) 630 newly diagnosed APL patients received ATRA combined to or followed by daunorubicin-cytarabine chemotherapy (for a total of three courses), with or without (randomization) maintenance treatment by 6MP and methotrexate and/or intermittent ATRA.
1,7 A total of 582 (92.5%) patients achieved hematological CR and 154 (26.4%) relapsed, after 5-120 months. Nineteen of those first relapses occurred more than 4 years after CR achievement ('late relapses'), representing 12.3% of the relapses and 3.2% of the patients who achieved CR. Median age of the 19 patients was 45 years (range 20-68), and male/female ratio was 7/12. Median time to relapse was 72 months (range 50-120), and all relapses involved the bone marrow only. t(15;17) translocation and/or PML-RARa rearrangement was seen in all cases at relapse, confirming that those relapses were APL and not therapy-related AML.
8
Salvage treatment consisted of ATRA þ anthracycline-based chemotherapy in 14 patients, ATRA alone in two patients, anthracycline-based chemotherapy without ATRA in one patient, arsenic trioxide (As 2 O 3 ) in one patient and a combination of ATRA and As 2 O 3 in one patient. Seventeen of the 19 patients (89.4%) achieved a second hematological complete remission (CR2) and two patients experienced early death. Post-remission treatment consisted of allogeneic stem cell transplantation in three patients, autologous stem cell transplantation in five patients, consolidation and maintenance chemotherapy with or without ATRA in seven patients and maintenance with ATRA alone in two patients. Fourteen of the 17 (82%) patients remained in CR2 after 5 þ to 78 þ months. Two patients had a second relapse after nine and 22 months and died, and one patient developed secondary MDS and died. Second haematological complete remission was longer than CR1 in five cases and shorter in two cases (comparison between CR2 duration was not possible in the other patients, still in CR2 but with short follow-up). Three-years survival from relapse was 77%.
By comparison to patients who did not relapse and patients who relapsed after less than 4 years (Table 1) , patients with late relapse did not differ for age and initial platelets. They were more often female patients (M/F ¼ 0.54 vs 2; P ¼ 0.01) and had lower initial WBC counts than patients who relapsed earlier than 4 years (mean WBC 7800/mm 3 vs 18 000/mm 3 , Po0.05) but these features did not significantly differ from patients who did not relapse (M/F ¼ 0.86 and mean WBC ¼ 8700/mm 3 ). Percentages of patients with late relapse who had not received maintenance treatment (known in APL 93 trial to have reduced the incidence of relapse) were intermediate between those with early relapses and those who did not relapse: 15, 26 and 32% for no relapse, late relapse and early relapse, respectively, although differences were not statistically significant (Table 1) .
We finally tried to determine if early addition of chemotherapy to ATRA, which reduced the incidence of early relapses in APL 93 trial, 1 also had an impact on the incidence of late relapses. This analysis was restricted to the groups randomized between ATRA followed (after CR achievement) by chemotherapy, and ATRA combined to upfront chemotherapy (i.e. 306 patients of APL 93 trial). Five late relapses were seen after ATRA combined to chemotherapy (2.7% of the 184 patients and 23% of all relapsing patients included in that treatment arm), vs four after ATRA followed by chemotherapy (3.2% of the 122 patients and 15% of all relapsing patients included in that treatment arm), showing the absence of obvious impact of early addition of chemotherapy on the occurrence of late relapses.
Thus, first late relapse (44 years) was seen in about 3% of this large cohort of APL patients treated with ATRA and intensive chemotherapy. This incidence is similar to that previously reported after treatment of APL with chemotherapy alone. 5, 6 This finding further confirms that the addition of ATRA to chemotherapy not only delays relapses but also reduces their incidence. Initial characteristics of the patients who had late relapses were rather those of 'low-risk' APL (especially with WBCo10 000/mm 3 and female predominance). On the other hand, the proportion of patients with late relapse who had received maintenance was slightly lower than that of patients who did not relapse, suggesting that systematic use of maintenance treatment in APL may further reduce the incidence of late relapses. Whether those late relapses were due to reemergence of the initial leukemic clone or due to occurrence of a secondary APL clone remains unknown.
In our experience, the prognosis of late relapses was overall favorable, in spite of the fact that they generally occurred before As 2 O 3 -now considered as the treatment of choice for relapsing APL patients -was available. The Wnt signaling pathway is important in hematolymphopoiesis. 1 A critical target of Wnt signaling is b-catenin. b-catenin is normally bound to a multi-protein complex comprising axin, APC, GSK3b, CKIa and PP2A, where b-catenin is phosphorylated by GSK3b, leading to ubiquitylation and proteasome degradation. Activation of the canonical Wnt pathway inhibits GSK3b, resulting in hypophosphorylation and stabilization of b-catenin, which translocates to the nucleus, activates transcription of other target genes, and contributes to tumorigenesis.Activation of Wnt signaling has been implicated in leukemias.
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2,3 The Wnt inhibitory factor 1 (Wif-1) is an extracellular protein that binds Wnt, negatively regulating the Wnt pathway.
4 Hence, Wif-1 downregulation may contribute to Wnt pathway activation.In leukemias, promoter hypermethylation of genes involved in cell-cycle control and signaling pathways is frequent. 5, 6 In this study, we tested the hypothesis that epigenetic inactivation of Wif-1 might lead to activation of Wnt signaling in acute leukemia. We further investigated if Wif-1 hypermethylation might be of clinicopathological significance.Diagnostic bone marrow samples were obtained from 25 patients with acute lymphoblastic leukemia (ALL; T-cell: 2; pre-B: 1; early B-precursor: 3; common: 19), 32 patients with acute promyelocytic leukemia (APL), and 50 patients with other subtypes of acute myeloid leukemia (AML; M1: 12; M2: 20; M4: 6; M5: 9; M6: 3). Five leukemic cell lines, U937, HL60, Raji, Jurkat and NB4 were also tested. Methylation-specific polymerase chain reaction (MSP) for aberrant promoter methylation was performed as described. 5 The primers for the methylated (M-MSP) and unmethylated (U-MSP) promoters of Wif-1 are shown in Table 1. 7 DNA from eight normal bone marrow donors was used as negative control, while methylated control DNA (CpGenome Universal Methylated DNA, Intergen, New York, NY, USA) was used as positive control in all the experiments. Cycling conditions for MSP were as follows: 951C for 4 min; 35 cycles of 951C for 45 s, specific annealing temperature for 30 s, and 721C for 30 s; and a final extension of 10 min at 721C MSP products were electrophoresed in 6% non-denaturing polyacrylamide gel, and visualized under ultraviolet light after staining with ethidium bromide.
None of the normal bone marrow samples showed Wif-1 methylation. The positive and negative controls showed the expected MSP results (Figure 1a ). Direct sequencing of the M-MSP product also confirmed the specificity of the MSP (Figure 1b) . Of the leukemic cell lines examined, Wif-1 was unmethylated in HL60 and Jurkat, but hemizygously methylated in Raji, NB4 and U937 (Figure 2a) . At diagnosis, Wif-1 methylation was detected in five (25%) of 20 ALL patients (Tcell: 1; early B precursor: 1; common: 3). Interestingly, in AML patients, Wif-1 methylation was found only in APL and not in any of the other subtypes of AMLs (Figure 2b ) (15/32, 47% versus 0/50, P ¼ 0.0001, w 2 -test). To confirm the biological significance of Wif-1 methylation, the APL cell line NB4 was tested. NB4 cells were seeded in 25 cm 2 culture flasks at 10 6 cells/ml, and treated with 3 mM 5-azacytidine (5-AC, Sigma, St Louis, MO, USA) for 5 days. Cells were harvested daily for mRNA. Quantitative polymerase chain reaction (Q-PCR) for Wif-1 was performed with a Wif-1 primer/TaqMan probe set (Assay-on-Demandt Applied Biosystems, Foster City, CA, USA) according to the manufacturer instructions, using GAPDH as the internal reference. Wif-1 expression relative to GAPDH was calculated with the DC T method (User Bulletin #2, PE Biosystems) 8 
